T1	Participants 52 127	postmenopausal women with advanced, hormone-receptor-positive breast cancer
T2	Participants 464 517	patients with hormone-receptor-positive breast cancer
T3	Participants 556 588	outpatient clinics and hospitals
T4	Participants 590 743	We enrolled postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment
T5	Participants 1466 1536	enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
T6	Participants 2501 2601	women with previously treated hormone-receptor-positive locally advanced or metastatic breast cancer
